Thank you for contacting me about Kadcyla.
I appreciate your concerns surrounding cancer drugs, I am aware that the National Institute for Health and Care Excellence (NICE) is currently updating its guidance on the use of Kadcyla, as a treatment for secondary breast cancer.
I know that a great importance is placed on drugs that can increase the life expectancy of those with cancer and therefore NICE applies as much flexibility as it can when looking at new life-extending treatments. Unfortunately, NICE has previously found that the price being charged for Kadcyla by the pharmaceutical company which manufacturers it was too high in relation to the benefits it gives for it to be recommended for routine commissioning in the NHS.
Draft updated NICE guidance on Kadcyla has been published for consultation and NICE's final guidance is expected in March 2017. Kadcyla will continue to be available through the Cancer Drugs Fund while the NICE appraisal is ongoing.
Thank you again for taking the time to contact me.
MP for Central Devon
Comptroller of the Household and Government Pairing Whip